Evaluation of the Clinical Value of Urinary NMP22 as a Marker in the Screening and Surveillance of Transitional Cell Carcinoma  of the Urinary Bladder

Chahal, R.; Darshane, A.; Browning, Anthony J.; Sundaram, S.K.

doi:10.1159/000049809

Cited by 18 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The resulting sensitivity and specificity of the NMP22 test in separated and voided urine is slightly lower compared to the results published so far in the literature, which are about 88 and 96% [7][8][9] . The sensitivity of cytological methods was considerably lower than that of NMP22, but the specificity of the cytological methods, whether in voided or separated urine, was higher than with NMP22, which corresponds to the literature findings -sensitivity of NMP22 being 65-78%, cytology 30-54%, and specificity of NMP22 being 40-70% and cytology 78-99% [10,11] .…”

Section: Discussioncontrasting

confidence: 70%

Diagnostic Value of the Nuclear Matrix Protein 22 Test and Urine Cytology in Upper Tract Urothelial Tumors

Jovanović¹,

Soldatović

Janjic³

et al. 2011

Urol Int

View full text Add to dashboard Cite

Objective: To investigate the diagnostic value of the nuclear matrix protein 22 (NMP22) test in comparison to urine cytology for the detection of upper tract urothelial carcinoma. Patients and Methods: Patients with transitional cell carcinoma of the upper urinary tract (n = 34) and patients with renal calculosis (n = 25) were included in this study. Voided urine samples and separated catheter urine specimens were assayed for NMP22 and cytological examination. Results: The sensitivity of the NMP22 test in separated and voided urine was 73.2 and 70.5%, respectively, compared to 64.7 and 58.8% of urine cytology. The specificity of the NMP22 test in separated and voided urine was 88 and 92%, respectively, compared to 96 and 96% of urine cytology. The combination of separated and voided urine is the best method because the sensitivity is 79.41% and specificity 88%. There is a high agreement of the NMP22 test in voided and separated urine (kappa = 0.795, p < 0.01), indicating that the voided urine is adequate for diagnosis. Conclusions: The NMP22 test has higher sensitivity but lower specificity than cytology. The combination of these two tests could be a very useful diagnostic method for detection of upper urothelial tumors.

show abstract

Section: Discussioncontrasting

confidence: 70%

Diagnostic Value of the Nuclear Matrix Protein 22 Test and Urine Cytology in Upper Tract Urothelial Tumors

Jovanović¹,

Soldatović

Janjic³

et al. 2011

Urol Int

View full text Add to dashboard Cite

show abstract

“…[52][53][54][55][56][57][58][59][60][61][62][63] For example, for the marker NMP22, sensitivities ranged from 6.0-100% and specificities from 62-92%. With BTA-stat, specificities were reported in the range of 69-73%; and in studies investigating UroVysion FISH, sensitivities ranged from 61-100% and specificities from 71.4-93%.…”

Section: Discussionmentioning

confidence: 99%

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015

Kassouf

Aprikian

Black

et al. 2016

CUAJ

View full text Add to dashboard Cite

This initiative was undertaken in response to concerns regarding the variation in management and in outcomes of patients with bladder cancer throughout centres and geographical areas in Canada. Population-based data have also revealed that real-life survival is lower than expected based on data from clinical trials and/or academic centres. To address these perceived shortcomings and attempt to streamline and unify treatment approaches to bladder cancer in Canada, a multidisciplinary panel of expert clinicians was convened last fall for a two-day working group consensus meeting. The panelists included urologic oncologists, medical oncologists, radiation oncologists, patient representatives, a genitourinary pathologist, and an enterostomal therapy nurse. The following recommendations and summaries of supporting evidence represent the results of the presentations, debates, and discussions. Methodology

show abstract

“…In this process, gene mutations in tumor suppressor genes such as p53 on chromosome 17p-, or p16 on chromosome 9q-are thought to be very important, on the basis of both immunological and molecular biological investigations. [1][2][3][4][5][6][7] Furthermore, many tumor markers in urine samples, such as Cyfra 21-1 8 and prostate stem cell antigen, 9 as well as bladder tumor antigen (BTA) and nuclear matrix protein 22 (NMP22), [10][11][12][13][14] have been found to be effective for the detection of recurrent bladder cancers. In recent years, fluorescence in situ hybridization (FISH) has been employed to detect chromosomal abnormalities in various malignant tumors, and it has proven to be very useful.…”

Section: Introductionmentioning

confidence: 99%

Noninvasive detection of alterations in chromosome numbers in urinary bladder cancer cells, using fluorescence in situ hybridization

et al. 2004

View full text Add to dashboard Cite

show abstract

Evaluation of the Clinical Value of Urinary NMP22 as a Marker in the Screening and Surveillance of Transitional Cell Carcinoma of the Urinary Bladder

Cited by 18 publications

References 20 publications

Diagnostic Value of the Nuclear Matrix Protein 22 Test and Urine Cytology in Upper Tract Urothelial Tumors

Diagnostic Value of the Nuclear Matrix Protein 22 Test and Urine Cytology in Upper Tract Urothelial Tumors

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015

Noninvasive detection of alterations in chromosome numbers in urinary bladder cancer cells, using fluorescence in situ hybridization

Contact Info

Product

Resources

About